Our directors have previously published widely in top journals across our three main focuses — repurposed drugs for chronic conditions, post-viral syndromes and PACVS, and environmental health and drug safety. Our work is cited by national advisory committees on PACVS and continues to shape clinical treatment and health policy.
Mechanistic and clinical research on long COVID, post-vaccination syndrome (PACVS), spike protein pathology, and immune dysregulation.
12 publicationsEvidence on repurposing existing compounds — herbals, nutraceuticals, AI-identified candidates, and approved drugs — for cancer, neurodegeneration, and metabolic disease.
20 publicationsResearch on endocrine disruptors, pharmacovigilance, environmental determinants of disease, and long-term safety of pharmaceutical interventions.
10 publicationsEvery contribution goes directly to research, open-access publication costs, and building the evidence base for underserved conditions.